Reason for request
Indication extension
Summary of opinion
Favourable opinion for reimbursement in the following indication: “KEYTRUDA, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of KEYTRUDA (pembrolizumab), in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is substantial in the indication: “in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
|
Clinical Added Value
| moderate |
Considering:
- demonstration in a randomised, double-blind, phase 3 study (KN-A18 trial, including 56.7% FIGO 2014 stage III - IVA patients) of the superiority of pembrolizumab compared to chemoradiotherapy, for the treatment of FIGO stage IB2-IIB and III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy, in terms of:
- progression-free survival with an HR = 0.70 (95% CI = [0.55; 0.89]; p = 0.002 < the predefined threshold of 0.0172), 7% patients progressed or died in the experimental group versus 29.0% patients in the control group. The median PFS was not reached in either of the two groups.
- overall survival with an HR = 0.67 (95% CI = [0.50; 0.90]; p = 0.0040 < 0.01026), 2% deaths in the experimental group versus 20.5% patients in the control group. The median OS was not reached in either of the two groups.
And despite:
- the absence of any formal conclusion that can be drawn based on the quality of life findings;
- a safety profile deemed to be acceptable compared to chemoradiotherapy but marked by an excess toxicity with grade ≥ 3 AEs reported in 78.3% of patients in the pembrolizumab group and 70.0% of patients in the placebo group). In addition, 20.6% of patients in the pembrolizumab group and 14.9% of patients in the placebo group had an AE resulting in definitive discontinuation of pembrolizumab treatment.
The Committee deems that KEYTRUDA (pembrolizumab) 25 mg/ml, concentrate for solution for infusion, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), provides a moderate clinical added value (CAV III) compared to chemoradiotherapy.
|
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
AmGbeDt1pt6bn68V